دورية أكاديمية
Molecular Changes in the Adipose Tissue Induced by Rheumatoid Arthritis: Effects of Disease-Modifying Anti-Rheumatic Drugs
| العنوان: | Molecular Changes in the Adipose Tissue Induced by Rheumatoid Arthritis: Effects of Disease-Modifying Anti-Rheumatic Drugs |
|---|---|
| المؤلفون: | Arias de la Rosa, Iván, Escudero-Contreras, Alejandro, Ruiz-Ponce, Miriam, Román-Rodríguez, Cristóbal, Pérez-Sánchez, Carlos, Ábalos-Aguilera, María del Carmen, Ortega-Castro, Rafaela, Alcaide, Juan, Murri, Mora, Font, Pilar, Calvo-Gutiérrez, Jerusalem, Luque-Tevar, Maria, Patiño-Trives, Alejandra Maria, Guzmán-Ruiz, Rocío, Malagón, Maria del Mar, Tinahones, Francisco José, Collantes-Estévez, Eduardo, López-Pedrera, Chary, Barbarroja, Nuria |
| المساهمون: | Arias de la Rosa,I, Escudero-Contreras,A, Ruiz-Ponce,M, Román-Rodríguez,C, Pérez-Sánchez,C, Ábalos-Aguilera,MC, Ortega-Castro,R, Font,P, Calvo-Gutiérrez,J, Luque-Tevar,M, Patiño-Trives,AM, Collantes-Estévez,E, López-Pedrera,C, Barbarroja,N Rheumatology Service/Deparment of Medicine and Surgical Sciences, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), University of Cordoba, Reina Sofia Hospital, Cordoba, Spain. Alcaide,J, Murri,M, Tinahones,FJ Biomedical Research Institute (IBIMA), Service of Endocrinology and Nutrition, Malaga Hospital Complex, Virgen de la Victoria, Malaga, Spain. Alcaide,J, Malagón,MM, Tinahones,FJ Centros de Investigació n Biomédica en Red (CIBER) Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain. Guzmán-Ruiz,R, Malagón,MM Department of Cell Biology, Physiology and Immunology, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain., This research was funded by grants from the Instituto de Salud Carlos III (PI17/01316 and PI18/00837), co-financed by the European Regional Development Fund (ERDF), a way to make Europe, Spain, MINECO (RyC-2017-23437), and the Spanish Inflammatory and Rheumatic diseases Network (RIER, RD16/0012/0015). CL-P was supported by a contract from the Junta de Andalucia (Nicolas Monardes programme). |
| بيانات النشر: | Frontiers |
| سنة النشر: | 2021 |
| المجموعة: | Sistema Sanitario Público de Andalucía (SSPA): Repositorio |
| مصطلحات موضوعية: | Rheumatoid arthritis, Obesity, Inflammation, Adipose tissue, cDMARDs, Leflunomide, Hydroxychloroquine, Methotrexate, Artritis reumatoide, Obesidad, Inflamación, Tejido adiposo, Antirreumáticos, Leflunomida, Hidroxicloroquina, Metotrexato, Medical Subject Headings::Anatomy::Tissues::Connective Tissue::Adipose Tissue, Medical Subject Headings::Persons::Persons::Age Groups::Adult, Medical Subject Headings::Organisms::Eukaryota::Animals, Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antirheumatic Agents, Medical Subject Headings::Diseases::Immune System Diseases::Autoimmune Diseases::Arthritis, Rheumatoid, Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cross-Sectional Studies, Medical Subject Headings::Check Tags::Female, Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans, Medical Subject Headings::Check Tags::Male, Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Rodentia::Muridae::Murinae::Mice, Medical Subject Headings::Persons::Persons::Age Groups::Adult::Middle Aged, Medical Subject Headings::Diseases::Nutritional and Metabolic Diseases::Nutrition Disorders::Overnutrition::Obesity |
| الوصف: | Disease severity, progression and response to therapy might be worse in obese rheumatoid arthritis (RA) patients, but paradoxically, obesity also might protect from radiographic joint damage. Thus, the intricate relationship between obesity and RA needs urgent clarification. The aim of this study was to assess the influence of obesity on the onset and development of RA and to determine whether arthritis could modify the adipose tissue biology and whether conventional Disease Modifying Anti-Rheumatic Drugs (cDMARDs) can modulate these alterations. Two strategies were followed: (1) clinical profiling of two cohorts of RA: non-obese and obese patients; and (2) mechanistic studies carried out in both a collagen-induced arthritis (CIA) in an obese mouse model and 3T3-L1 adipocytes treated with cDMARDs (leflunomide, methotrexate, and hydroxychloroquine). In our cohort of RA patients with low-moderate disease activity, the presence of obesity was not related to a higher activity of the disease; actually, disease activity score 28-erythrocyte sedimentation rate (DAS28-ESR) was reduced in the obese RA patients. However, the induction of arthritis promoted transcriptomic changes in the adipose tissue under obesity condition in the obese CIA model. Treatment with hydroxychloroquine reduced weight and insulin resistance, accompanied by beneficial metabolic effects in the adipose tissue. These molecular changes in adipose tissue were also observed after methotrexate administration. In sum, arthritis might affect directly the inflammatory burden and metabolic alterations associated with obesity in adipose tissue. Clinicians should be cautious measuring the activity of the disease in obesity and managing the best therapeutic options for the metabolic comorbidities of these patients, where the combination of hydroxychloroquine and methotrexate should be considered to improve adipose tissue dysfunction in obese RA. ; Yes |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1664-3224 |
| العلاقة: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.744022/fullTest; Arias de la Rosa I, Escudero-Contreras A, Ruiz-Ponce M, Román-Rodríguez C, Pérez-Sánchez C, Ábalos-Aguilera MDC, et al. Changes in the Adipose Tissue Induced by Rheumatoid Arthritis: Effects of Disease-Modifying Anti-Rheumatic Drugs. Front Immunol. 2021 Oct 13;12:744022; http://hdl.handle.net/10668/4179Test; PMC8549628 |
| DOI: | 10.3389/fimmu.2021.744022 |
| الإتاحة: | https://doi.org/10.3389/fimmu.2021.744022Test http://hdl.handle.net/10668/4179Test |
| حقوق: | Atribución 4.0 Internacional ; http://creativecommons.org/licenses/by/4.0Test/ ; open access |
| رقم الانضمام: | edsbas.6C4263C4 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 16643224 |
|---|---|
| DOI: | 10.3389/fimmu.2021.744022 |